Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of storing cells in a viable state
Reexamination Certificate
2001-10-23
2003-12-02
Lankford, Jr., Leon B. (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of storing cells in a viable state
C424S725000, C435S001100, C435S040000, C435S325000, C435S360000
Reexamination Certificate
active
06656729
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compositions of matter which are effective in inhibiting apoptotic cell death.
BACKGROUND OF THE INVENTION
Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Recent studies of apoptosis have implied that a common metabolic pathway leading to cell death may be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation, and infection by human immunodeficiency virus (HIV). Wyllie (1980)
Nature
284:555-556; Kanter et al. (1984)
Biochem. Biophys. Res. Commun.
118:392-399; Duke and Cohen (1986)
Lymphokine Res.
5:289-299; Tomei et al. (1988)
Biochem. Biophys. Res. Commun.
155:324-331; and Kruman et al. (1991)
J. Cell. Physiol.
148:267-273; Ameisen and Capron (1991)
Immunol. Today
12:102-105; and Sheppard and Ascher (1992)
J. AIDS
5:143-147. Agents that affect the biological control of apoptosis thus have therapeutic utility in numerous clinical indications.
Apoptotic cell death is characterized by cellular shrinkage, chromatin condensation, cytoplasmic blebbing, increased membrane permeability and internucleosomal DNA cleavage. Gerschenson et al. (1992)
FASEB J.
6:2450-2455; and Cohen and Duke (1992)
Ann. Rev. Immunol.
10:267-293.
All references cited herein both supra and infra are hereby incorporated herein by reference.
A variety of food supplements containing, in part, partially processed plant extracts have been used to ameliorate the gastrointestinal disorders that often accompany chemotherapy, radiation and AIDS. The supplements generally contain carbohydrates, fat and plant protein hydrolysates. See, e.g., Tomei and Cope et al. in Apoptosis The Molecular Basis of Cell Death (1991) Cold Spring Harbor Laboratory Press.
Several proteinase inhibitors derived from plant extracts have anticarcinogenic activity. Troll et al. (1987)
Adv. Cancer Res.
49:265-283. The Bowman-Birk inhibitors are the best described of these inhibitors. Birk (1985)
Int. J. Pep. Pro. Res.
25:113-131. Bowman-Birk inhibitors are described as a family of disulfide bonded proteins with a molecular weight of about 8 kD which suppress cellular transformation. Chou et al. (1974)
Proc. Natl. Acad. Sci. USA
71:1748-1752; Yavelow et al. (1985)
Proc. Natl. Acad. Sci. USA
82:5395-5399; and Yavelow et al. (1983)
Cancer Res.
(Suppl.) 43:2454s-2459s. Crude soybean extracts containing Bowman-Birk inhibitors have been described. Kennedy et al. U.S. Pat. No. 4,793,996; PCT publication No. WO 94/20121; and Kennedy, A. R. (1994)
Cancer Res.
(Suppl) 54:1999s-2005s. Bowman-Birk inhibitors have also been described immunologically. WO 90/03574; and U.S. Pat. Nos. 4,959,310; and 5,053,327. Bowman-Birk inhibitors have also been found to have activity in degranulation of macrophages. Japanese Patent No. 63051335.
Lysophosphatidic acid (LPA) is found in a variety of plant products as are a variety of phospholipids. LPA has been found to have a variety of physiological activities including mitogenesis, growth factor and as an anti-wrinkle agent. U.S. Pat. Nos. 4,263,286; 4,746,652; 5,326,690; and 5,340,568. LPA is reviewed in detail by Moolenaar (1994)
TICB
4:213-219; and Eichholtz et al. (1990)
Biochem. J.
291:677-680.
SUMMARY OF THE INVENTION
The present invention encompasses methods of obtaining compositions that inhibit apoptosis and the compositions obtained thereby. The compositions are termed phytogenic apoptosis inhibitors (PAIs). The invention encompasses physiologically acceptable compositions suitable for administering the PAIs in an amount sufficient to modulate apoptosis. The invention further encompasses methods of use of the PAIs.
REFERENCES:
patent: 4263286 (1981-04-01), Nakajima et al.
patent: 4340586 (1982-07-01), Bekierkunst et al.
patent: 4695590 (1987-09-01), Lippman
patent: 4746652 (1988-05-01), Buckalew, Jr. et al.
patent: 4793996 (1988-12-01), Kennedy et al.
patent: 4818540 (1989-04-01), Chien et al.
patent: 4938961 (1990-07-01), Collins et al.
patent: 4959310 (1990-09-01), Brandon et al.
patent: 4959353 (1990-09-01), Brown et al.
patent: 5053327 (1991-10-01), Brandon et al.
patent: 5093505 (1992-03-01), Nishino et al.
patent: 5130298 (1992-07-01), Cini et al.
patent: 5140043 (1992-08-01), Darr et al.
patent: 5217717 (1993-06-01), Kennedy et al.
patent: 5238965 (1993-08-01), Piazza et al.
patent: 5326690 (1994-07-01), Xu et al.
patent: 5330972 (1994-07-01), Cope
patent: 5340568 (1994-08-01), Piazza et al.
patent: 5635187 (1997-06-01), Bathurst et al.
patent: 5636187 (1997-06-01), Fujii et al.
patent: 5759548 (1998-06-01), Bathurst et al.
patent: 6306398 (2001-10-01), Bathurst et al.
patent: 0626177 (1994-11-01), None
patent: 63-51335 (1988-03-01), None
patent: WO 90/03574 (1990-04-01), None
patent: WO 94/20121 (1994-09-01), None
patent: WO 94/25621 (1994-11-01), None
Ameisen et al.,Immunol. Today, 12(4): 102-105 (1991).
Billings et al.,Carcinogenesis, 12(4): 653-657 (1991).
Birk et al.,Biochem. J., 87: 281-284 (1963).
Birk,Int. J. Peptide Protein Res., 25: 113-131 (1985).
Bligh et al.,Can. J. Biochem. Physiol., 37(8): 911-917 (1959).
Chang et al.,Mol. Carcinogen, 3: 226-232 (1990).
Chien et al.,J. Thorac. Cardiovasc. Surg., 95: 55-61 (1988).
Chien et al.,Cardiovascular Research, 22(10): 739-745 (1988).
Chien et al.,Circulation, 78(suppl. II):III-58-III-65 (1988).
Chien et al.,Hibernation Induction Trigger for Organ Preservation, C. Kerkaporta, ed., R.G. Landes Company, Chapter 6: 106-115 (1993).
Chien et al.,Medical Intelligence Unit, R.G. Landes Co., Austin, Texas (1993).
Chou et al.,Proc. Natl. Acad. Sci. USA, 71(5): 1748-1752 (1974).
Christie,Oily Press, Dundee, Scotland, (1987).
Christie,Oily Press, Dundee, Scotland, (1989).
Cohen et al.,Annu. Rev. Immunol., 10: 267-293 (1992).
Collins et al.,Kidney International, 42:(suppl. 38):S-197-S-202 (1992).
Dawson et al.,Data for Biochemical Research, 3rded., Clarendon Press, Oxford (1986).
Dominguez-Bello et al.,J. Agric. Food Chem., 41: 2045-2050 (1993).
Duke et al.,Lumphokine Res., 5(4): 289-299 (1986).
Eichholtz et al.,Biochem. J., 291: 677-680 (1993).
Funk et al.,J. Nutr., 121: 1673-1683 (1991).
Funk et al.,J. Nutr., 121: 1684-1692 (1991).
Gerschenson et al.,FASEB J., 6: 2450-2455 (1992).
Gertler et al.,J. Nutr., 91: 358-370 (1967).
Hamilton et al., Richwood et al. (eds.), IRL Press at Oxford University Press (1992).
Hardy et al.,Meth. Enzymol., 230: 208-225 (1994).
Hasdai et al.,Brit. J. Nutr., 62: 529-537 (1989).
Jungalwala,Phospholipids in Nervous Tissues, Eichenberg (ed.), John Wiley & Sons, pp. 1-44, (1985).
Kakade et al.,J. Nutr., 103: 1772-1778 (1973).
Kanter et al.,Biochem. Biophys. Res. Commun., 118(12): 392-399 (1984).
Kates, Burdon et al. (eds:), Elsevier.
Kennedy,Cancer Res. (Suppl.), 54: 1999s-2005s (1994).
Khayambashi et al.,J. Nutr., 89: 455-464 (1966).
Kruman et al.,J. Cell. Physiol. 148: 267-273 (1991).
Moolenaar,TICB, 4:213-219 ((1994).
Neely et al.,Am. J. Physiol., 212: 804-814 (1967).
Oates et al.,Am. J. Physiol., 250 G9-G14 (1986).
Patton et al.,J. Lipid Res., 23:190-196 (1982).
Sambrook et al., eds.Molecular Cloning. A Laboratory Manual, vols. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
Schnebli et al.,Proc. Natl. Acad. Sci. USA, 69(12): 3825-3827 (1972).
Sheppard et al.,J. AIDS, 5: 143-147 (1992).
Simpson,Cir. Res., 56(6): 884-894 (1985).
Singal, ed., Kluwer Academic Publishers, Boston, (1988).
Smetana et al.,Nephron, 61: 68-72 (1992).
Sojar et al.,Meth. Enzymol., 138: 341-350 (1987).
Su-Fan et al.,Am. J. Physiol., 246 (Heart Circ. Physio. 15): H296-H301 (1984).
Su-Fan et al.,Am. J. Physiol., 252(Heart Circ. Physiol. 21): H243-H251 (1987).
Takasaki et al.,Meth. Enzymol., 83: 263-268 (1982).
Tomei et al.,Biochem.
Barr Philip J.
Bathurst Ian Cyril
Bradley John D.
Tomei L. David
Lankford , Jr. Leon B.
Sheridan & Ross P.C.
Sky High, LLC
LandOfFree
Compositions which inhibit apoptosis, methods of purifying... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions which inhibit apoptosis, methods of purifying..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions which inhibit apoptosis, methods of purifying... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3181593